Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Psoriatic Arthritis (PsA) is an inflammatory condition estimated to affect around 150,000 people in the UK. Two thirds will suffer progressive joint damage with associated disability. A significant proportion of patients require treatment with biologic therapies as conventional disease-modifying drugs are not always effective.  However there are an increasing number of different biologic and targeted synthetic DMARDs available and we cannot currently predict which people will respond to which of these therapies.  Around 30% of patients do not respond well to their first biologic therapy and need to switch to a different mode of action.  Personalised medicine to select the right biologic for each patient offers a way forward as discussed in a recent article by Hussein Al-Mossawi and Laura Coates from NDORMS https://www.nature.com/articles/s41584-018-0043-3

 

Dr Coates and the Ox-PACE team are currently recruiting to MONITOR a cohort study for PsA patients from which 2 interventional Trials Within Cohort (TWiCs) are due to start soon, SPEED and POISE.  These studies will test the personalisation of therapy based on clinical disease characteristics with the aim of improving disease control and patient’s quality of life.

Similar stories

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.